glp 1 based therapeutics summit Home GLP-1 Summit 2025
Description
Key differences between Tirzepatide (Mounjaro) and Semaglutide (Ozempic) for type 2 diabetes and weight loss
Digestive health symptoms are the #1 barrier to GLP-1 adherence
Arizona is one of 32 states where Medicaid doesnt cover drugs such as Trulicity and Ozempic without a diagnosis of diabetes, heart failure, high blood pressure or other related ailments.
Insulinogenic index (IGI) and whole-body insulin sensitivity were calculated using glucose and insulin levels from the OGTT
GLP-1 agonists such as semaglutide (marketed as Ozempic and Wegovy) have surged
